C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) C12Q 1/26 (2006.01) G01N 33/68 (2006.01)
Patent
CA 2466596
Based on the unexpected identification of a CYP46 gene polymorphism as a novel genetic risk factor that links cholesterol metabolism to Alzheimer's disease, the present invention provides a method of diagnosing or prognosticating Alzheimer s disease, or determining the propensity or predisposition of a subject to develop Alzheimer s disease. The method comprises detecting the presence or absence of a variation in the CYP46 gene which encodes the enzyme cholesterol 24-hydroxylase.
A partir de l'identification de manière inattendue d'un polymorphisme du gène CYP46 en tant que nouveau facteur de risque qui associe le métabolisme du cholestérol à la maladie d'Alzheimer, la présente invention fournit un procédé permettant le diagnostic ou le pronostic de la maladie d'Alzheimer, ou la détermination de la propension ou la prédisposition d'un sujet à développer la maladie d'Alzheimer. Le procédé comporte la détection de la présence ou de l'absence d'une variation dans le gène CYP46 codant pour l'enzyme de cholestérol 24-hydroxylase
Hock Christoph
Nitsch Roger M.
Papassotiropoulos Andreas
Streffer Johannes R.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
University Of Zurich
LandOfFree
Cyp46 genotype determination for risk and treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyp46 genotype determination for risk and treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyp46 genotype determination for risk and treatment... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1661617